b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="Publisher" Owner="NLM">\n        <PMID Version="1">32275807</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>27</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1549-490X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Apr</Month>\n                        <Day>10</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The oncologist</Title>\n                <ISOAbbreviation>Oncologist</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.</ArticleTitle>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2019-0756</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with diffuse large B-cell lymphoma (DLBCL) with concurrent hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection have distinct clinical features. Nevertheless, the prognostic value of HBsAg in DLBCL in the rituximab era remains unclear.</AbstractText>\n                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study to investigate the clinical relevance of HBsAg in immunocompetent patients with DLBCL treated with homogeneous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone between 2002 and 2016.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 416 analyzed patients, 98 (23.6%) were HBsAg positive. HBsAg positivity was associated with a younger age and more advanced stage at diagnosis, more frequent hepatic impairment during perichemotherapy, and a trend of higher National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) score at diagnosis. Compared with the HBsAg-negative patients, the HBsAg-positive patients had a lower overall response rate (76.5% vs. 85.5%, p = .043), poorer 5-year overall survival (OS) rate (57.2% vs. 73.5%, p &lt; .001), and shorter 5-year progression-free survival (PFS) rate (47.2% vs. 60.7%, p = .013). Multivariate analyses showed that HBsAg positivity was an independent unfavorable prognostic indicator for OS and PFS. A scoring system incorporating HBsAg positivity, the NCCN-IPI score, and serum albumin levels proved to be useful for stratifying prognostically relevant subgroups of patients with DLBCL.</AbstractText>\n                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated that HBV infection is uniquely relevant to DLBCL. HBsAg might serve as a novel biomarker to improve clinical risk stratification of patients with DLBCL in areas with high prevalence of HBV infection. Further research investigating the etiopathogenesis of HBV infection in DLBCL is imperative.</AbstractText>\n                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">A considerable disparity exists regarding the prognostic relevance of hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection in patients with diffuse large B-cell lymphoma (DLBCL). In this large, retrospective cohort study from an area with high prevalence of HBV infection, the authors demonstrated that HBsAg was an independent unfavorable factor significantly associated with survival, highlighting its potential as a novel prognostic indicator to improve the risk stratification of patients with DLBCL in the rituximab era.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 AlphaMed Press 2020.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Cheng</LastName>\n                    <ForeName>Chieh-Lung</ForeName>\n                    <Initials>CL</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0001-5442-1079</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Huang</LastName>\n                    <ForeName>Sheng-Chuan</ForeName>\n                    <Initials>SC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chen</LastName>\n                    <ForeName>Jia-Hong</ForeName>\n                    <Initials>JH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wei</LastName>\n                    <ForeName>Chao-Hung</ForeName>\n                    <Initials>CH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fang</LastName>\n                    <ForeName>Wei-Quan</ForeName>\n                    <Initials>WQ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Su</LastName>\n                    <ForeName>Tung-Hung</ForeName>\n                    <Initials>TH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yuan</LastName>\n                    <ForeName>Chang-Tsu</ForeName>\n                    <Initials>CT</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Liu</LastName>\n                    <ForeName>Jia-Hau</ForeName>\n                    <Initials>JH</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Taicheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chuang</LastName>\n                    <ForeName>Ming-Kai</ForeName>\n                    <Initials>MK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Laboratory Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tien</LastName>\n                    <ForeName>Hwei-Fang</ForeName>\n                    <Initials>HF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>04</Month>\n                <Day>10</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Oncologist</MedlineTA>\n            <NlmUniqueID>9607837</NlmUniqueID>\n            <ISSNLinking>1083-7159</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Diffuse large B-cell lymphoma</Keyword>\n            <Keyword MajorTopicYN="N">Hepatitis B surface antigen</Keyword>\n            <Keyword MajorTopicYN="N">Hepatitis B virus infection</Keyword>\n            <Keyword MajorTopicYN="N">Prognosis</Keyword>\n            <Keyword MajorTopicYN="N">Risk stratification</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>25</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>aheadofprint</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32275807</ArticleId>\n            <ArticleId IdType="doi">10.1634/theoncologist.2019-0756</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>References</Title>\n            <Reference>\n                <Citation>Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kim JH, Bang YJ, Park BJ et al. Hepatitis B virus infection and B-cell non-Hodgkin\'s lymphoma in a hepatitis B endemic area: A case-control study. Jpn J Cancer Res 2002;93:471-477.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: A cohort study. Lancet Oncol 2010;11:827-834.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin\'s lymphoma. Haematologica 2006;91:554-557.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chen MH, Hsiao LT, Chiou TJ et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin\'s lymphoma. Ann Hematol 2008;87:475-480.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Su TH, Liu CJ, Tseng TC et al. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin\'s lymphoma and multiple myeloma. Aliment Pharmacol Ther 2019;49:589-598.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dalia S, Chavez J, Castillo JJ et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. Leuk Res 2013;37:1107-1115.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Li M, Gan Y, Fan C et al. Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies. J Viral Hepat 2018;25:894-903.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang F, Xu RH, Luo HY et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008;8:115.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Deng L, Song Y, Young KH et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: Unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 2015;6:25061-25073.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ren W, Ye X, Su H et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood 2018;131:2670-2681.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Yan X, Zhou M, Lou Z et al. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes. J Cancer Res Ther 2018;14:S248-S253.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lim ST, Fei G, Quek R et al. The relationship of hepatitis B virus infection and non-Hodgkin\'s lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007;79:132-137.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Law MF, Lai HK, Chan HN et al. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. Eur J Cancer Care (Engl) 2015;24:117-124.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wei Z, Zou S, Li F et al. HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: Result from a multicenter retrospective analysis in China. Med Oncol 2014;31:845.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liu Z, Li S, Liu Y et al. PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection. PLoS One 2017;12:e0180390.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Xie W, Zhou D, Hu K et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Exp Ther Med 2013;6:109-114.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Al-Mansour MM, Alghamdi SA, Alsubaie MA et al. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. Infect Agent Cancer 2018;13:18.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hsu HY, Chang MH, Chen DS et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-307.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhou Z, Sehn LH, Rademaker AW et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\'Etudes des Lymphomes de l\'Adulte. Blood 2010;116:2040-2045.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Melchardt T, Troppan K, Weiss L et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. Br J Haematol 2015;168:239-245.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Matsue K, Kimura S, Takanashi Y et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:4769-4776.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pei SN, Chen CH, Lee CM et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-262.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kim SJ, Hsu C, Song YQ et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013;49:3486-3496.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wilcox RA, Ristow K, Habermann TM et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011;25:1502-1509.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004;4:78-85.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kim DH, Baek JH, Chae YS et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21:2227-2230.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cox MC, Nofroni I, Laverde G et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008;141:265-268.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Weiner GJ. Rituximab: Mechanism of action. Semin Hematol 2010;47:115-123.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liu Z, Li S, Guo W et al. MYC gene rearrangements are closely associated with poor survival of diffuse large B cell lymphoma with hepatitis B virus infection. Biomed Res Int 2017;2017:1967648.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zhao X, Guo X, Xing L et al. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Cell Death Dis 2018;9:61.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wang Y, Wang H, Pan S et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. J Cancer 2018;9:1575-1581.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pontisso P, Vidalino L, Quarta S et al. Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. Autoimmun Rev 2008;8:13-17.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Umeda M, Marusawa H, Seno H et al. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J Hepatol 2005;42:806-812.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'